title: Bone marrow angiogenesis in systemic mast cell disease.
abstract: Mast cells may participate in tumor angiogenesis through the release of angiogenic cytokines from their secretory granules. To gain additional insight into the role of mast cells in bone marrow angiogenesis, we performed a semiquantitative measurement of bone marrow microvessel density in 52 consecutive adult patients with systemic mast cell disease (SMCD). The results were examined for potential correlations with mast cell expression of angiogenic cytokines and with other histologic features of the bone marrow. Standard immunohistochemical methods were used to visualize bone marrow microvessels (CD34 staining) and mast cell expression of transforming growth factor-beta, basic fibroblast growth factor, and their respective receptors. An increase in microvessel density was demonstrated in 32 of the 52 patients (62%) with SMCD, and the degree of bone marrow angiogenesis did not correlate with either the mast cell expression pattern of the study cytokines or the presence (23 patients) or absence (29 patients) of an associated hematologic disorder. In the 29 patients without an associated hematologic disorder, microvessel density was correlated significantly with the presence of an abnormal pattern of hematopoiesis but not with the degree of bone marrow involvement by mast cells. Furthermore, areas occupied by mast cell lesions were often devoid of neovascularization. We conclude that bone marrow angiogenesis characterizes a percentage of patients with SMCD and that the pathogenesis may not necessarily be linked to the mast cells themselves.
authors.affiliation: Divisions of Hematopathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Jin-Young
authors.initials: JY
authors.lastname: Baek
authors.forename: Chin-Yang
authors.initials: CY
authors.lastname: Li
authors.forename: Animesh
authors.initials: A
authors.lastname: Pardanani
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Butterfield
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D001853:Bone Marrow / Q000098:blood supply* / Q000473:pathology; D015331:Cohort Studies; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006402:Hematologic Diseases / Q000150:complications; D006410:Hematopoiesis; D006801:Humans; D007150:Immunohistochemistry; D008407:Mast Cells / Q000378:metabolism / Q000473:pathology; D008415:Mastocytosis / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D008833:Microcirculation / Q000737:chemistry / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism; D018125:Receptors, Transforming Growth Factor beta / Q000378:metabolism; D012189:Retrospective Studies; D016212:Transforming Growth Factor beta / Q000378:metabolism
chemical_list: D018952:Antigens, CD34; D017468:Receptors, Fibroblast Growth Factor; D018125:Receptors, Transforming Growth Factor beta; D016212:Transforming Growth Factor beta; D016222:Fibroblast Growth Factor 2